Misplaced Pages

Fulvestrant

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 07:56, 26 January 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Wik). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 07:56, 26 January 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Wik)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Fulvestrant
Clinical data
Pregnancy
category
  • D
Routes of
administration		Intramuscular injection
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding99%
Elimination half-life40 days
Identifiers
IUPAC name
  • 13-methyl-7-- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta phenanthrene-3,17-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.170.955 Edit this at Wikidata
Chemical and physical data
FormulaC32H47F5O3S
Molar mass606.772 g/mol g·mol
3D model (JSmol)
SMILES
  • FC(F)(F)C(F)(F)CCCS(=O)CCCCCCCCCC3Cc1c(ccc(O)c1)2CC4((23)CC4O)C
  (verify)

Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Clinical uses

Fulvestrant is a Selective Estrogen Receptor Down-Regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

External links

References

  1. S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan (2005). "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release". Mol Cell Endocrinol. 239 (1–2): 27–36. doi:10.1016/j.mce.2005.04.008. PMID 15950373.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Template:Sex hormones

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: